Company: OSRH
Filing Date: 2025-08-19
Form Type: PRE 14A
Source: 0001213900-25-078140
Chunk: 20

Company: OSR Holdings, Inc.
Filing Date: 2025-08-19
Form: PRE 14A
Chunk 20
---
 the private and public scientific
research sectors.

Dr. Seng Chin Mah became a Director of the Company
as of the Closing of the Business Combination. Dr. Mah has been Chairman of the Board of BioVersys AG since 2009. He was previously
Chief Executive Officer of the Canyon Pharmaceuticals Group AG (2009-2021) and has over 30 years’ experience in the pharma
and biotech industry. Prior to Canyon Pharmaceuticals, he was Head of Development of the Integration Office during the integration of
Chiron into Novartis (2005-2008) and held other positions at Novartis, including Global Head of Clinical Safety and Epidemiology (2001-2005);
Head of Drug Regulatory Affairs Europe (1997-2001); and oversight responsibility for Clinical Quality Assurance (2001-2005). Dr. Mah
was also a member of the Novartis Corporate Executive Group (2001-2005) and a member of the Board of Directors for Novartis Europharm
Ltd. (1997-2005). During his tenure with Novartis and Ciba (1990-2008), he drove key drug development and regulatory programs, and led
major business results including numerous global registrations of major products. He has held several research and academia positions
(Ciba-Geigy Ltd., 1987-1988; National University of Singapore, 1989-1990). Dr. Mah was awarded The Frost &
Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants, which recognized Canyon Pharmaceuticals Group AG
for the development and launch of Iprivask (desirudin for injection). Dr. Mah earned a BS in Pharmacology from
University of London (1984) and a PhD in Biochemistry from University of Basel (1987). Dr. Mah is well qualified to serve as
a Director because of his extensive knowledge and experience in strategic decision-making, late-stage clinical development and regulatory
experience within the Pharma and Biotech industry.

<div align='center'>10</div>

Jin Whan Parkhas been a Director of the Company
since February 2023. Mr. Park has served as Chief Executive Officer of JWP & Partners since founding the firm in 2011.
From 2006 to 2012, Mr. Park was Director and Head of Investment Banking at Yuhwa Securities, where he advised on M&A transactions
for corporate clients listed on the KOSDAQ.